Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study

Anna Song, Wankyu Eo, Sehyun Kim, Bumsang Shim and Sookyung Lee

Abstract

Background: Advanced hepatobiliary cancers are highly lethal cancers that require precise prediction in clinical practice. Serum ferritin level increases in malignancy and high serum ferritin level is associated with poor survival in various cancers. This study aimed to identify whether serum ferritin could independently predict the overall survival (OS) of patients with advanced hepatobiliary cancers.

Methods: The retrospective cohort study was performed by reviewing medical records of patients with advanced hepatobiliary cancers from June 2006 to September 2016. The demographic and clinicopathological characteristics as well as the biochemical markers were evaluated at the initiation of Korean medicine (KM) treatment. The OS was calculated using Kaplan-Meier estimates. The Cox proportional hazard model was used to identify the independent prognostic significance of serum ferritin for survival.

Results: The median OS of all subjects was 5.1 months (range, 0.5–114.9 months). The median OS of group with low ferritin levels and that with high ferritin levels was 7.5 months (range, 0.7–114.9 months) and 2.8 months (range, 0.5–22.8 months), respectively (P < 0.001). The results of the univariate analysis showed that the Eastern Cooperative Oncology Group Performance Status (ECOG-PS) (P = 0.002), tumor type (P = 0.001), prior treatment (P = 0.023), serum ferritin (P < 0.001), hemoglobin (P = 0.002), total bilirubin (P = 0.002), gamma-glutamyl transpeptidase (P = 0.007), albumin (P = 0.013), white blood cell (P = 0.002), and C-reactive protein (CRP) (P < 0.001) were significant factors for the patients’ survival outcome. On multivariate analysis controlling confounding factors, ferritin (P = 0.041), CRP (P = 0.010), ECOG-PS (P = 0.010), and tumor type (P = 0.018) were identified as independent prognostic factors for survival.

Conclusions: These results indicate that serum ferritin is a valid clinical biochemical marker to predict survival of patients with advanced hepatobiliary cancers.

Keywords: Hepatocellular carcinoma, Biliary tract neoplasms, Survival, Prognosis, Ferritins
Background

Hepatobiliary cancers, including hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) are often incurable and highly lethal cancers. The BTC are classified as either cholangiocarcinoma of the bile duct or gall bladder cancer, according to the site of the tumor. In addition, HCC is the fourth most common cancer and the second leading cause of cancer death in South Korea [1]. Although the incidence of BTC is relatively low, the heavy disease burden is associated with poor survival outcome. Even if BTC is diagnosed at an early stage and curative resection is performed, a short recurrence-free survival (11–20 months) and a high recurrence rate (53–62%) have been reported in previous studies [2–5]. Furthermore, most patients are initially diagnosed with advanced stage hepatobiliary cancer [6].

Patients with advanced hepatobiliary cancers have limited systemic chemotherapy options: sorafenib for advanced HCC and cisplatin plus gemcitabine for advanced BTC [7–9]. Unlike other types of cancer, the progression of hepatobiliary cancers is deeply related to liver function. Progression of tumor causes deterioration of the liver function, but repeated treatment can also damage liver function; thus, selecting an appropriate treatment modality is difficult in clinical practice. For a decade, patients with advanced hepatobiliary cancers have had limited standard treatment options and most of them underwent anticancer therapy with limited or only short-term survival gain.

To provide optimized treatment for patients, precise survival prediction is required in clinical practice. Identifying indicators that can predict the survival outcome of patients with advanced hepatobiliary cancers will help practitioners provide optimal care and management of these patients. According to recent studies, Child-Pugh score, body mass index (BMI), and aspartate aminotransferase (AST) for HCC and Eastern Cooperative Oncology Group Performance Status (ECOG-PS), carcinoembryonic antigen, carbohydrate antigen 19–9, hemoglobin (Hb), white blood cell (WBC), and albumin for BTCs have been identified as potential prognostic biomarkers for predicting survival in advanced hepatobiliary cancers [2, 10, 11].

Ferritin is an iron storage protein that is abundant in intracellular compartments. A small amount of ferritin also exists in blood and is called serum ferritin. Serum ferritin is a surrogate marker of stored iron, and 1 ng/mL of serum ferritin is equal to 8 mg of stored iron [12]. The level of serum ferritin tends to increase with age and is relatively higher in men than in women [13]. Elevated serum ferritin often indicates iron over-load, but it also increases in inflammation, liver disease, and malignancy [14–19]. Previous studies have reported that high serum ferritin is associated with poor prognosis in pancreatic cancer, colorectal cancer, lung cancer, peripheral T-cell lymphoma, and HCC [16–20]. However, the prognostic significance of serum ferritin for survival in patients with advanced hepatobiliary cancers has not been investigated.

Therefore, this study was performed to identify the potential prognostic impact of serum ferritin level in predicting survival in patients with advanced hepatobiliary cancers treated with Korean medicine (KM).

Methods

This study was based on a retrospective cohort design and approved by the Institutional Review Board of Kyung Hee University Hospital at Gangdong (KHNMC-OH-IRB 2016–10-006).

Study subjects

For this study, we reviewed medical records of patients with hepatobiliary cancers from June 2006 to September 2016. Inclusion criteria were as follows: patients with hepatobiliary cancer classified as stage IV disease according to the American Joint Committee on Cancer Tumor Node Metastasis staging (7th ed., 2010), those aged > 20 years treated with KM monotherapy, those who had a serum ferritin value measured before the treatment, and those who had an ECOG-PS of 0–2.

Patients who were concurrently treated with KM combined with any conventional cancer therapy, such as transarterial chemoembolization, radiofrequency ablation (RFA), high-intensity focused ultrasound, surgery, chemotherapy, and radiotherapy, were excluded in this study to eliminate the effects of conventional cancer therapy. In addition, patients who had undergone conventional cancer treatment within 4 weeks from the initial laboratory tests were excluded to avoid the effects of conventional treatment on the biochemical markers. At the time of laboratory testing, patients with signs of inflammation or those treated with antibiotics were also excluded to rule out the influence induced by inflammation. (Fig. 1).

Demographic, clinicopathological, and biochemical factors

Patient demographic and clinicopathological characteristics and biochemical markers were investigated. Demographic and clinicopathologic characteristics included age, gender, ECOG-PS, BMI, tumor type, and prior treatments. Biochemical markers, including serum ferritin, Hb, total bilirubin, AST, alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γ-GT), prothrombin time international normalized ratio (PT INR), albumin, WBC, and C-reactive protein (CRP), were assessed from peripheral blood testing. The cut-off values of biochemical markers, except CRP and serum ferritin, were determined according to the reference ranges of markers. In this study, the cut-off value for CRP was defined as
1.0 mg/L, which is commonly used in systemic inflammation and cancer studies [21, 22]. Serum ferritin was categorized into two groups according to the iron overload criteria suggested by the World Health Organization, which defined low serum ferritin as \( \leq 200 \text{ ng/mL} \) in men and \( \leq 150 \text{ ng/mL} \) in women. A high level of serum ferritin was defined as > 200 ng/mL in men and > 150 ng/mL in women [23].

Overall survival
Overall survival (OS) was defined as the time from the first visit to the time of death from any cause. When the patient was lost to follow-up or the death was not recorded, the patient was censored. The survival time of censored patients was defined by the period from the first visit to the last day of follow-up or to February 25, 2017, the date on which the survival was investigated.

Treatment
For the treatment or management of patients, the *Rhus verniciflua stokes* (RVS) extract that has been reported with anticancer effect was used as the anticancer agent in this study. This extract is known to have anti-migration, anti-proliferative, and apoptotic effects [24, 25]. The RVS was extracted via the standardized method with water at 95 °C, concentrated, and lyophilized in powdered form. After removing the toxic allergen urushiol, the major compounds were examined to ensure consistent quality of the extract [26]. A 500 mg of RVS extract was filled in one capsule. Patients received three oral capsules of RVS extract in a day (a total of 1500 mg) as an anticancer agent. In addition, herbal medicine and acupunctures were also used based on the doctors’ judgment and consideration of the patient’s symptoms.

Statistical analysis
The OS of patients was calculated using Kaplan-Meier estimates, and the differences between the survival data was compared using the log-rank test. If the survival time was incomplete, right censoring was used in survival analysis. Subgroup analysis according to ferritin level was performed using Chi-square tests. Univariate and multivariate analyses using a Cox proportional hazard model were conducted. A multivariate analysis was performed with statistically significant factors from the univariate analysis \((P\text{-value} \leq 0.05)\) and controlling confounding factors, such as age and gender. Pearson correlation coefficient tests were performed to evaluate the relationship between serum ferritin and other biochemical markers. The data were analyzed using SPSS (version 18.0; SPSS Inc., Chicago, IL, USA). A \(P\)-value \(\leq 0.05\) was considered statistically significant.

Results
A total of 80 patients, comprising 27 (33.8%) females and 53 (66.3%) males, with advanced hepatobiliary cancers were analyzed. The mean age was 59.7 years. The demographic, clinicopathological, and biochemical characteristics are
summarized in Table 1. A total of 33 (41.3%) HCC cases, 44 (55.0%) BTC cases, and 3 (3.8%) combined HCC and CC (cHCC-CC) cases were included. The majority of patients (68.8%) had undergone at least one prior treatment. The median time from the diagnosis of stage IV cancer to the first visit for the initiation of KM treatment was 4.4 months (range, 0.1–43.3 months).

The median OS of all patients was 5.1 months (range, 0.5–114.9 months) (Fig. 2). The median OS of HCC, BTC, and cHCC-CC was 8.1 months (range, 0.7–114.9 months), 4.5 months (range, 0.5–22.6 months), and 2.1 months (range, 2.0–3.8 months), respectively.

The median OS of the low-ferritin group was 7.5 months (range, 0.7–114.9 months), and the median OS for the high ferritin group was 2.8 months (range, 0.5–22.8 months) \( (P < 0.001) \) (Fig. 2). Patients with a high serum ferritin showed a significantly shorter survival compared with patients with low serum ferritin.

The low-ferritin group included 45 patients, whereas the high-ferritin group had 35. As shown in Table 2, no statistical differences were noted in age, gender, tumor type, prior treatment, BMI, Hb, total bilirubin, AST, ALT, PT INR, and albumin between the two groups. However, an elevated serum ferritin level was associated with worsening of ECOG-PS \( (P = 0.004) \) and increasing level of \( \gamma \)-GT \( (P < 0.001) \), CRP \( (P < 0.001) \), and WBC count \( (P = 0.013) \).

The results of the univariate analysis according to demographic and clinicopathological factors are shown in Table 3. The ECOG-PS of 2 compared with ECOG-PS of 0 or 1 (HR = 2.67, 95% CI: 1.44–4.92; \( P = 0.002 \)) and no history of prior treatment (HR = 1.77, 95% CI: 1.08–2.89; \( P = 0.023 \)) were associated with shortened OS. In addition, the OS between tumor types was significantly different. The BTC or cHCC-CC had a significantly increased hazard ratio compared with HCC (HR = 2.50, 95% CI: 1.49–4.19; \( P = 0.001 \)).

The results of the univariate analysis according to biochemical factors are shown in Table 3. Biochemical factors were dichotomized either based on the reference values of each marker or based on previous studies.

**Table 1** Baseline characteristics in patients with advanced hepatobiliary cancers \( (n = 80) \)

| Variables | Values | Total (n) | Percent (%) |
|-----------|--------|-----------|-------------|
| **Clinicopathological factors** | | | |
| Age (years) | < 65 / \( \geq \) 65 | 50/30 | 62.5/37.5 |
| Gender | Female / Male | 27/53 | 33.8/66.3 |
| ECOG-PS | 0 / 1 / 2 | 14/52/14 | 17.5/65.0/17.5 |
| BMI (kg/m\(^2\)) | < 23 / \( \geq \) 23 | 44/36 | 55.0/45.0 |
| Tumor Type | HCC / BTC / cHCC-CC | 33/44/3 | 41.3/55.0/3.8 |
| Previous anticancer therapy | No / Yes | 25/55 | 31.3/68.8 |
| Prior surgery | No / Yes | 44/36 | 55.0/45.0 |
| Prior chemotherapy | No / 1st line / 2nd line / \( \geq \) 3rd line | 47/17/7/9 | 58.8/21.3/8.8/11/3 |
| Prior radiotherapy | No / Yes | 66/14 | 82.5/17.5 |
| Prior TACE | No / 1 / 2 / \( \geq \) 3 | 60/3/5/12 | 75.0/3.8/6.3/15.0 |
| Prior RFA | No / Yes | 71/9 | 88.8/11.3 |
| **Laboratory factors** | | | |
| Ferritin (ng/mL) | Low\(^a\) / High\(^b\) | 45/35 | 56.3/43.8 |
| Hb (g/dL) | Low\(^c\) / High\(^d\) | 50/30 | 62.5/37.5 |
| Total bilirubin (mg/dL) | \( \leq 1.2 \) / \( > 1.2 \) | 64/16 | 80.0/20.0 |
| AST (IU/L) | \( < 40 \) / \( \geq 40 \) | 37/43 | 46.3/53.8 |
| ALT (IU/L) | \( < 40 \) / \( \geq 40 \) | 46/34 | 57.5/42.5 |
| \( \gamma \)-GT (IU/L) | \( \leq 66 \) / \( > 66 \) | 25/55 | 31.3/68.8 |
| PT INR | \( \leq 1.16 \) / \( > 1.16 \) | 57/23 | 71.3/28.8 |
| Albumin (g/dL) | \( < 3.5 \) / \( \geq 3.5 \) | 13/67 | 16.3/83.8 |
| WBC (x10\(^3\)/μL) | \( < 10.0 \) / \( \geq 21.00 \) | 70/10 | 87.5/12.5 |
| CRP (mg/L) | \( < 10.0 \) / \( \geq 21.00 \) | 40/40 | 50.0/50.0 |

COG-PS Eastern cooperative oncology group performance status, BMI body mass index, TACE transarterial chemoembolization, RFA radiofrequency ablation, Hb hemoglobin, AST aspartate aminotransferase, ALT alanine aminotransferase, \( \gamma \)-GT gamma-glutamyl transpeptidase, PT INR prothrombin time international normalized ratio, WBC white blood cell, CRP c-reactive protein, HCC hepatocellular carcinoma, BTC biliary tract cancers, cHCC-CC combined hepatocellular-cholangiocarcinoma

\( ^{a}\) female \( < 150 \) male \( \leq 200 \); \( ^{b}\) female \( > 150 \) male \( > 200 \); \( ^{c}\) female \( < 12.0 \) male \( < 13.0 \); \( ^{d}\) female \( \geq 12.0 \) male \( \geq 13.0 \)
A high serum ferritin level (HR = 2.47, 95% CI: 1.54–3.96; \( P < 0.001 \)), total bilirubin > 1.2 mg/dL (HR = 2.44, 95% CI: 1.37–4.35; \( P = 0.002 \)), \( \gamma \)-GT > 66 IU/L (HR = 1.98, 95% CI: 1.20–3.25; \( P = 0.007 \)), WBC ≥ 10.0 × 10^3/μL (HR = 2.98, 95% CI: 1.49–5.98; \( P = 0.002 \)), and CRP ≥ 10.0 mg/L (HR = 3.23, 95% CI: 1.99–5.25;
< 0.001) were significantly associated with poor survival outcomes. Low Hb level (< 12.0 g/dL for female and < 13.0 g/dL for male) (HR = 2.24, 95% CI: 1.35–3.73; P = 0.002) and albumin < 3.5 g/dL (HR = 2.16, 95% CI: 1.18–3.98; P = 0.013) were significantly associated with a short OS.

Based on the results of the multivariate analysis, serum ferritin was a significant independent prognostic factor after adjusting for gender, age, ECOG-PS, and other biochemical markers (Table 3). Although age and gender were not significant prognostic factors for survival in the univariate analysis, the multivariate analysis was performed after controlling for age and gender, which influence the level of serum ferritin [13]. A high level of serum ferritin was significantly associated with short survival time (HR = 1.96, 95% CI: 1.03–3.73; P = 0.041). Other significant independent prognostic factors for survival were ECOG-PS, tumor type, and CRP. Patients with ECOG-PS of 2 had a significantly shorter survival time than those with ECOG-PS of 0 or 1 (HR = 2.61, 95% CI: 1.26–5.44; P = 0.010). The BTC or cHCC-CC had an increased hazard ratio of mortality compared with HCC (HR = 2.18, 95% CI: 1.15–4.15; P = 0.018). An elevated CRP was significantly associated with poor survival outcomes (HR = 2.12, 95% CI: 1.20–3.76; P = 0.010).

According to correlation analysis, ALT (r = 0.23, P = 0.037), γ-GT (r = 0.23, P = 0.038), PT INR (r = 0.33, P = 0.002), albumin (r = −0.28, P = 0.012), WBC (r = 0.46, P < 0.001), and CRP (r = 0.68, P < 0.001) were significantly correlated with serum ferritin (Table 4).

### Table 2 Subgroup analysis according to serum ferritin level (n = 80)

| Variables                  | Values                  | Ferritin (ng/mL) | P-value |
|---------------------------|-------------------------|------------------|---------|
|                           | Low<sup>a</sup>         | High<sup>b</sup> |
|                           | n = 45                  | n = 35           |         |
| Age (years)               | < 65 / ≥65              | 31/14            | 0.181   |
| Gender                    | Female / Male           | 15/30            | 0.930   |
| ECOG-PS                   | 0–1 / 2                 | 42/3             | 0.004   |
| BMI (kg/m<sup>2</sup>)    | < 23 / ≥23              | 23/22            | 0.430   |
| Tumor Type                | HCC / BTC or cHCC-CC    | 22/23            | 0.116   |
| Previous antitumor therapy| No / Yes                | 11/34            | 0.136   |
| Hb (g/dL)                 | Low<sup>c</sup> / High<sup>d</sup> | 28/17 | 0.950   |
| Total bilirubin (mg/dL)   | ≤1.2 / > 1.2            | 37/8             | 0.570   |
| AST (IU/L)                | < 40 / ≥40              | 24/21            | 0.150   |
| ALT (IU/L)                | < 40 / ≥40              | 27/18            | 0.610   |
| γ-GT (IU/L)               | ≤66 / > 66              | 22/23            | < 0.001 |
| PT INR                    | ≤1.16 / > 1.16          | 32/13            | 0.980   |
| Albumin (g/dL)            | < 3.5 / ≥3.5            | 7/38             | 0.850   |
| WBC (×10<sup>3</sup>/μL)  | < 10.0 / ≥10.0          | 43/2             | 0.013   |
| CRP (mg/L)                | < 10.0 / ≥10.0          | 31/14            | < 0.001 |

ECOG-PS: Eastern cooperative oncology group performance status, BMI: body mass index, Hb: hemoglobin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, γ-GT: gamma-glutamyl transpeptidase, PT INR: prothrombin time international normalized ratio, WBC: white blood cell, CRP: C-reactive protein, HCC: hepatocellular carcinoma, BTC: biliary tract cancers, cHCC-CC: combined hepatocellular-cholangiocarcinoma

<sup>a</sup> female ≤150 male ≤200, <sup>b</sup> female > 150 male > 200, <sup>c</sup> female < 12.0 male < 13.0, <sup>d</sup> female ≥12.0 male ≥13.0

**Discussion**

Hepatobiliary cancers are fatal cancers usually diagnosed at a progressed stage. Only a minority of patients are eligible for curative treatments [28]. The National Comprehensive Cancer Network recommends sorafenib, a molecular target agent, as a first-line standard treatment for patients with advanced HCC based on two phase III clinical trials [7, 8]. In South Korea, the median OS of patients with advanced HCC who were treated with sorafenib is 4.7 months [29].

For advanced BTC patients with good performance status, gemcitabine and cisplatin combination therapy is the first-line treatment [9]. However, similar to advanced HCC, the available systemic therapy in BTC is also limited, and the median OS of gemcitabine and cisplatin combination therapy is only 9.8 months [30]. In addition, there is no established second-line therapy for disease progression after initial treatment. Therefore, some patients with advanced HCC or advanced BTC who relapsed from the initial treatment or showed a refractory disease status are re-treated with various treatments, participate in clinical trials, or receive the best supportive care. Some patients are reluctant to...
Table 3 Univariate and multivariate analysis of factors affecting overall survival of patients with advanced hepatobiliary cancers (n = 80)

| Variables                              | Values | Univariate Hazard Ratio (95% CI) | P-value | Multivariate Hazard Ratio (95% CI) | P-value |
|----------------------------------------|--------|----------------------------------|---------|------------------------------------|---------|
| Clinicopathological factors            |        |                                  |         |                                    |         |
| Age (years)                            | < 65 vs. ≥65 | 1.45 (0.91–2.33)                  | 0.121   | 0.96 (0.56–1.65)                   | 0.880   |
| Gender                                 | Male vs. Female | 1.51 (0.93–2.45)                  | 0.096   | 1.55 (0.86–2.78)                   | 0.144   |
| ECOG-PS                                | 0–1 vs. 2 | 2.67 (1.44–4.92)                  | 0.002   | 2.61 (1.26–5.44)                   | 0.010   |
| BMI (kg/m²)                            | < 23 vs. ≥23 | 0.70 (0.44–1.11)                  | 0.127   |                                    |         |
| Tumor Type                             | HCC vs. BTC or cHCC-CC | 2.50 (1.49–4.19)                  | 0.001   | 2.18 (1.15–4.15)                   | 0.018   |
| Previous anticancer therapy            | Yes vs. No | 1.77 (1.08–2.89)                  | 0.023   | 1.01 (0.53–1.90)                   | 0.980   |
| Prior surgery                          | Yes vs. No | 0.77 (0.49–1.21)                  | 0.250   |                                    |         |
| Prior chemotherapy                     | No vs. Yes | 1.31 (0.82–2.08)                  | 0.260   |                                    |         |
| Prior radiotherapy                     | No vs. Yes | 1.12 (0.62–2.00)                  | 0.710   |                                    |         |
| Biochemical factors                    |        |                                  |         |                                    |         |
| Ferritin (ng/mL)                       | Low<sup>a</sup> vs. High<sup>b</sup> | 2.47 (1.54–3.96)                  | <0.001  | 1.96 (1.03–3.73)                   | 0.041   |
| Hb (g/dL)                              | High<sup>c</sup> vs. Low<sup>d</sup> | 2.24 (1.35–3.73)                  | 0.002   | 1.50 (0.81–2.79)                   | 0.200   |
| Total bilirubin (mg/dL)                | ≤1.2 vs. > 1.2 | 2.44 (1.37–4.35)                  | 0.002   | 2.02 (1.00–4.07)                   | 0.051   |
| AST (IU/L)                             | < 40 vs. ≥40 | 1.56 (0.99–2.47)                  | 0.058   |                                    |         |
| ALT (IU/L)                             | < 40 vs. ≥40 | 0.85 (0.53–1.36)                  | 0.500   |                                    |         |
| γ-GT (IU/L)                            | ≤66 vs. > 66 | 1.98 (1.20–3.25)                  | 0.007   | 0.91 (0.46–1.80)                   | 0.790   |
| PT INR                                 | ≤1.16 vs. > 1.16 | 1.33 (0.81–2.19)                  | 0.260   |                                    |         |
| Albumin (g/dL)                         | ≥3.5 vs. < 3.5 | 2.16 (1.18–3.98)                  | 0.013   | 1.64 (0.77–3.49)                   | 0.198   |
| WBC (×10<sup>3</sup>/μL)               | < 100 vs. ≥100 | 2.98 (1.49–5.98)                  | 0.002   | 1.80 (0.79–4.11)                   | 0.165   |
| CRP (mg/L)                             | < 100 vs. ≥100 | 3.23 (1.99–5.25)                  | <0.001  | 2.12 (1.20–3.76)                   | 0.010   |

ECOG-PS: Eastern cooperative oncology group performance status; BMI: body mass index; Hb: hemoglobin; AST: aspartate aminotransferase; ALT: alanine aminotransferase; γ-GT: gamma-glutamyl transpeptidase; PT INR: prothrombin time international normalized ratio; WBC: white blood cell; CRP: c-reactive protein; HCC: hepatocellular carcinoma; BTC: biliary tract cancers; cHCC-CC: combined hepatocellular-cholangiocarcinoma; CI: confidence interval

* female ≤150 male ≤200; † female > 150 male > 200; ‡ female ≥120 male ≥130; § female < 120 male < 130

Sequential conventional therapy because of the uncertainty of the benefit and the risk of adverse events of second-line therapy.

In South Korea, KM is typically used for patients with advanced cancer who are not eligible for any conventional standard therapies. In this study, the main herbal medicine prescribed was RVS extract used as the anticancer agent. This extract has been used to treat cancer since the fifteenth century and is known for its antioxidant and anticancer effects. In addition, it has a low cytotoxicity and has been associated with growth inhibition and apoptotic effects in mouse tumorigenic hepatic cells [24, 25, 31–33]. The extract is used in various cancer treatments, long-term complete responses have been reported in two metastatic renal cell carcinomas, and the prolongation of OS with fewer adverse events has been reported in advanced non-small cell lung cancer and pancreatic cancer [34–36]. In hepatobiliary cancer, a patient with recurrent HCC after liver transplantation experienced prolonged survival when treated with RVS [37]. Regarding advanced hepatobiliary cancers, a clinical trial performed with treatment naïve patients reported 7.0 months of median OS [38]. Considering the majority of patients (68.8%) have undergone prior anticancer therapy and the median duration time to initiate RVS extract was 4.1 months after stage IV diagnosis, the 5.1 months median OS in present study could be regarded as a relatively positive clinical outcome.

Table 4 Correlation between serum ferritin and biochemical factors (n = 80)

| Variables | Correlation coefficients | P-value |
|-----------|--------------------------|---------|
| Hb (g/dL) | −0.13                    | 0.240   |
| Total bilirubin (mg/dL) | 0.18          | 0.117   |
| AST (IU/L) | 0.21                     | 0.064   |
| ALT (IU/L) | 0.23                     | 0.037   |
| γ-GT (IU/L) | 0.23                     | 0.038   |
| PT INR   | 0.33                     | 0.002   |
| Albumin (g/dL) | −0.28               | 0.012   |
| WBC (×10<sup>3</sup>/μL) | 0.46           | <0.001  |
| CRP (mg/L) | 0.68                     | <0.001  |

Hb: hemoglobin; AST: aspartate aminotransferase; ALT: alanine aminotransferase; γ-GT: gamma-glutamyl transpeptidase; PT INR: prothrombin time international normalized ratio; WBC: white blood cell; CRP: c-reactive protein.
For patients with advanced hepatobiliary cancers, precise prognosis is vital for deciding on further management because of the aggressive characteristics of advanced cancer. Identifying simple and easily accessible biomarkers for clinical application is necessary. To identify a potential biomarker for predicting survival, this study assessed the significance of serum ferritin as a potential prognostic factor in patients with advanced hepatobiliary cancers.

All 80 patients with advanced hepatobiliary cancers treated with KM only were diagnosed with stage IV disease, and the median time from the diagnosis of stage IV disease to the first visit to the cancer center for the initiation of KM was 4.4 months. The majority of patients (68.8%) had undergone at least one conventional therapy. The median survival of all the patients was 5.1 months, and elevated serum ferritin was significantly correlated with short OS ($P < 0.001$). Based on the results of univariate analyses, ECOG-PS, tumor type, prior treatment, serum ferritin, Hb, total bilirubin, $\gamma$-GT, albumin, WBC, and CRP significantly affected OS. In the multivariate analysis controlling confounding factors, serum ferritin was an independent prognostic factor for OS. This finding implies the prognostic impact of serum ferritin regardless of confounding biases, such as age, gender, ECOG-PS, tumor type, prior treatments, and other biochemical markers.

Regarding hepatobiliary cancers, only a few studies surveyed the relationship between serum ferritin level and OS. In HCC patients treated with RFA, high serum ferritin level was a negative risk factor for OS [16]. In patients with intrahepatic cholangiocarcinoma (ICC) undergoing surgical treatments, elevated serum ferritin level was also associated with poor survival outcomes [39]. These studies implied the potential prognostic impact of the serum ferritin level in newly diagnosed or early stage HCC and ICC but not in stage IV hepatobiliary cancers as well as relapsed or refractory disease.

Along with serum ferritin, ECOG-PS, tumor type, and CRP were the significant independent prognostic factors in advanced hepatobiliary cancer patients treated with KM. The ECOG-PS reflects the degree of physical mobility of patients and is repeatedly demonstrated to be a prognostic factor for OS in advanced cancer patients. Similar to previous studies, this study showed the significant relationship between ECOG-PS and the survival outcome [40]. In this study, the OS of advanced BTC and cHCC-CC were shorter than advanced HCC, revealing significantly higher mortality risk [41, 42]. This is the first study comparing the OS of advanced HCC, BTC, and cHCC-CC, and advanced HCC showed significantly longer OS than other tumor types. In addition, the present study also identified CRP as an independent prognostic factor predicting survival which agrees with the findings of previous studies [43, 44].

Ferritin is a 24-subunit protein capable of sequestrating up to 4500 iron atoms in non-toxic form. Ferritin has two types of subunits, namely, light-chain ferritin (L-ferritin) and heavy-chain ferritin (H-ferritin), and they have different functions and characteristics [45, 46]. The ratio of the two differs depending on the sites, and serum ferritin is rich in L-ferritin [47, 48]. L-ferritin concentration in serum is increased in malignancy [47]. The cancer-associated elevation of serum ferritin is most likely caused by an inflammatory state, and a study demonstrated that ferritin is secreted from tumor associated macrophage [49–51]. Due to KM treatment is based on the host rather than tumor, ferritin which is secreted by macrophages and responds to systemic inflammation could be a host based prognostic factor to reflect the status of patients.

Correlation analyses in this study showed significant positive correlations between serum ferritin and inflammation-related biochemical markers, CRP ($r = 0.68$, $P < 0.001$), and WBC ($r = 0.46$, $P < 0.001$) (Table 4). In subgroup analyses, according to serum ferritin level, CRP ($P < 0.001$) and WBC ($P = 0.013$) showed significantly different distribution depending on the serum ferritin level (Table 2). These findings support the correlation between serum ferritin and CRP and WBC in advanced hepatobiliary cancer patients treated with KM. Despite the significant positive correlations with CRP and WBC, only CRP was a significant prognostic marker in multivariate analysis on OS.

Aside from inflammation, damaged hepatobiliary cancer cells may also affect the value of serum ferritin because it was correlated with ALT ($r = 0.23$, $P = 0.037$), $\gamma$-GT ($r = 0.23$, $P = 0.038$), PT INR ($r = 0.33$, $P = 0.002$), and albumin ($r = 0.28$, $P = 0.012$). These results contradict a previous study on HCC that showed no correlation between serum ferritin and transaminase [52]. However, previous studies also showed associations between serum aminotransferase and serum ferritin, which was similar to this study result, suggesting that serum ferritin came from damaged cells, and damaged cells release iron-rich ferritin into the serum [53–55]. Our results also indicate that ECOG-PS, tumor type, and CRP can be considered with serum ferritin in predicting prognosis in patients with advanced hepatobiliary cancers.

This study was limited by its retrospective cohort design and the inclusion of a small number of study participants. Another limitation was the lack of iron-related biomarkers such as serum iron, transferrin, and total iron-binding capacity, because they were not routinely measured in clinical practice. Therefore, well-designed prospective studies are necessary to support the findings of this study.

**Conclusion**

This study investigated the clinical significance of serum ferritin as a prognostic factor for survival in advanced...
hepatobiliary cancer patients treated with KM. The increased serum ferritin was significantly associated with poor survival outcome, showing positive correlation with CRP. After controlling the confounding factors, serum ferritin was identified as an independent prognostic factor for survival in advanced hepatobiliary cancer patients treated with KM. This result implies that serum ferritin plays a significant role in predicting the prognosis for survival in patients with advanced hepatobiliary cancers.

Abbreviations
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; BTC: Biliary tract cancers; chCC-CC: Combined HCC and CC; CI: Confidence interval; CRP: C-reactive protein; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; Hb: Hemoglobin; HCC: Hepatocellular Carcinoma; HR: Hazard ratio; ICC: Intrahepatic cholangiocarcinoma; KM: Korean medicine; OS: Overall survival; PT INR: Prothrombin time international normalized ratio; RFA: Radiofrequency ablation; RVS: Rhus verniciflua stokes; WBC: White blood cell; y-GT: Gamma-glutamyl transpeptidase

Acknowledgements
We are grateful to the patients and clinicians.

Availability of data and materials
The raw data are not publicly available due to ethical restriction and local data protection regulations. All relevant data for the conclusions are included in this published article.

Authors’ contributions
SA analyzed the data and wrote the draft of manuscript; EW and KS formulated the research hypothesis and advised on statistical analyses; SB analyzed the data and wrote the draft of manuscript; EW and KS analyzed the data and wrote the draft of manuscript; All authors have read and approved the manuscript.

Ethics approval and consent to participate
This study was reviewed and approved by the Institutional Review Board of Kyung Hee University Hospital at Gangdong (KHIMC-CH-RB 2016–10-006). Informed consent was waived for all patients because the analysis used anonymous clinical data obtained after each patient agreed to treatment.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, South Korea. 2 Department of Medical Oncology and Hematology, College of Medicine, Kyung Hee University, Seoul, South Korea. 3 Department of Pathology, College of Medicine, Kyung Hee University, Seoul, South Korea. 4 Department of Clinical Oncology, College of Korean Medicine, Kyung Hee University Hospital at Gangdong, 892 Dongnam-ro, Gangdong-gu, Seoul 05278, Republic of Korea.

Received: 4 April 2018 Accepted: 24 May 2018
Published online: 07 June 2018

References
1. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49(2):292–305.
2. Woo SM, Yoon KA, Hong EK, Park WS, Han SS, Park SJ, et al. DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study. Oncotarget. 2017;8(46):81394–404.
3. Tabrizian P, Jibara G, Hechtman JF, Franssen B, Labow DM, Schwartz ME, et al. Outcomes following resection of intrahepatic cholangiocarcinoma. HPB (Oxford). 2015;17(4):344–51.
4. Hyder O, Hatzaras I, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013;153(6):811–8.
5. Jamagin WR, Ruo L, Little SA, Klimenta D, D’Angelica M, DelMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689–700.
6. Augustine MM, Fong Y. Epidemiology and risk factors of biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23(2):171–88.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(3):788–90.
8. Cheng AL, Kang YK, Chen Z, Tao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
9. Valle J, Wasan H, Palmer DH, Cunningham D, Anthony A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.
10. Park HS, Park JS, Chun YJ, Roh YH, Moon J, Chon HJ, et al. Prognostic factors and scoring model for survival in metastatic biliary tract Cancer. Cancer Res Treat. 2017;49(4):1127–39.
11. Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016;27(1):134–40.
12. Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol. 1973;26(10):770–2.
13. Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Ann Intern Med. 2000;134(1):98–104.
14. Tran TN, Eubanks SK, Schaffer KJ, Zhou CY, Linder MC. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood. 1997;90(12):4979–86.
15. Crowley KL, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(1):77–85.
16. Facciorusso A, Del Prette V, Antonino M, Neve V, Crucino N, Di Leo A, et al. Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. J Gastroenterol Hepatol. 2014;29(11):1905–10.
17. Ji M, Li XD, Shi HB, Ning ZH, Zhao WQ, Wang Q, et al. Clinical significance of serum ferritin in elderly patients with primary lung carcinoma. Tumour Biol. 2014;35(10):10195–9.
18. Kalousova M, Krechler T, Jachymova M, Kubena AA, Zak A, Zima T. Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumour Biol. 2012;33(5):1695–700.
19. Koyama S, Fujisawa S, Watanabe R, Iwabashi M, Hiibashi D, Ishii Y, et al. Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. Int J Lab Hematol. 2017;39(1):112–7.
20. Lee S, Song A, Eo W. Serum ferritin as a prognostic biomarker for survival in relapsed or refractory metastatic colorectal Cancer. J Cancer. 2016;7(8):957–64.
21. Song A, Eo W, Lee S. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients. World J Gastroenterol. 2015;21(43):12410–20.
22. Bettuzzi VR, Cercon M, Ravaoli M, Grazi GL, Ercolani G, Del Gaudio M, et al. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation. 2011;91(11):1279–85.
23. WHO. Iron deficiency anaemia: assessment, prevention and control. Geneva: WHO. 2001. http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/WHO_NHD_01_3/en/. Accessed 24 Dec 2016.
24. Park JH, Moon G. Effect of allergen removed Rhus Verniciflua extract on inhibition of tumor metastasis. J of Kor Traditional Oncology. 2010;15(1):47–61.
25. Son YQ, Lee KY, Lee JC, Jang HS, Kim JG, Jeon YM, et al. Selective antiproliferative and apoptotic effects of flavonoids purified from Rhus verniciflua stokes; WBC: White blood cell; y-GT: Gamma-glutamyl transpeptidase
verniciiflua Stokes on normal versus transformed hepatic cell lines. Toxicol Lett. 2005;155(1):115–25.
26. Yoon SW, Park SJ, Kim KS, Jung HS, Choi WC. The study on the process and quality control of Rhus Verniciiflua stokes extract (Nexia). J of Kor Traditional Oncology. 2006;6(1):9.
27. WHO, UNICEF, UNU. Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers. In: Geneva, World Health Organization; 2001.
28. Ryder SD. Hepatobiliary tumours. Medicine. 2015;43(10):619–23.
29. Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, et al. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. BMC Cancer. 2015;15:296.
30. Park K, Kim KP, Park S, Chang HM. Comparison of gencitabine plus cisplatin versus capetebin plus cisplatin as first-line chemotherapy for advanced biliary tract cancer. Asia Pac J Clin Oncol. 2017;13(1):13–20.
31. Jang HS, Kook SH, Son YO, Kim KJ, Jeon YM, Jang YS, et al. Flavonoids purified from Rhus verniciiflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells. Biochim Biophys Acta. 2005;1726(3):309–16.
32. Lee JC, Lee KY, Kim J, Na CS, Jung NC, Chung GH, et al. Extract from Rhus verniciiflua Stokes is capable of inhibiting the growth of human lymphoma cells. Food Chem Toxicol. 2004;42(9):1383–8.
33. Kim MJ, Choi WC, Barshinikov AM, Kobayashi A. Anticancer and antioxidant activity of allergen-removed extract in Rhus verniciiflua Stokes. Korean Journal of Medicinal Crop Science. 2002;10(4):288–93.
34. Lee SK, Jung HS, Eo WK, Lee SY, Kim SH, Shim BS. Rhus verniciiflua Stokes extract as a potential option for treatment of metastatic renal cell carcinoma: report of two cases. Ann Oncol. 2010;21(6):1383–5.
35. Lee J, Chae J, Lee S, Kim K, Eo W, Kim S, et al. The efficacy and safety of standardized allergen-removed Rhus verniciiflua extract as maintenance therapy after first-line chemotherapy in patients with advanced non-small cell lung Cancer. The American Journal of Chinese Medicine. 2013;41(4):773–87.
36. Lee S, Kim K, Jung H, Cheon S, Kim S, Eo W, et al. Efficacy and safety of standardized allergen-removed Rhus verniciiflua Stokes extract in patients with advanced or metastatic pancreatic cancer: a Korean single-center experience. Oncology. 2011;81(5–6):312–8.
37. Kim KS, Jung HS, Choi WC, Eo WK, Cheon SH. A case of recurred hepatocellular carcinoma refractory to doxorubicin after liver transplantation showing response to herbal medicine product, Rhus verniciiflua Stokes extract. Integr Cancer Ther. 2010;9(1):100–4.
38. Nimeiri HS, Singh DA, Kasra K, Taber DA, Ansari RH, Vokes EE, et al. The epothilone B analogue ixabepilone in patients with advanced hepatocellular cancers: a trial of the University of Chicago phase II consortium. Invest New Drugs. 2010;28(6):854–8.
39. Xun XD, Li Q. Surgical treatment of intrahepatic cholangiocarcinoma: a retrospective study of 104 cases. Cancer Biol Med. 2016;13(4):469–73.
40. Hauser CA, Stockler MR, Tattersall MH. Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer. 2006;14(10):999–1011.
41. Chiororai EG, Ramaubabhaia R, Yu M, Picus J, Buffil JA, Tong Y, et al. Phase II trial of etoritabine and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hossier oncology group G06-101. Oncologist. 2012;17(1):13.
42. Yoon YI, Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, et al. Postresection outcomes of combined hepatocellular carcinoma-cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2016;20(2):411–20.
43. Shiba H, Furukawa K, Fujiwara Y, Futagawa Y, Haruki K, Wakiyama S, et al. Postoperative peak serum C-reactive protein predicts outcome of hepatic resection for hepatocellular carcinoma. Anticancer Res. 2013;33(2):705–9.
44. Schweitzer N, Fischer M, Kistheim MM, Berhane S, Kottas M, Sinn M, et al. Risk estimation for biliary tract cancer: development and validation of a prognostic score. Liver Int. 2017.
45. Boyd D, Vecoli C, Belcher DM, Jain SK, Drysdale JW. Structural and functional relationships of human ferritin H and L chains deduced from cDNA clones. J Biol Chem. 1985;260(21):11755–61.
46. Orino K, Harada S, Natsuhori M, Takehara K, Watanabe K. Kinetic analysis of bovine spleen apoferritin and recombinant H and L chain homopolymers: iron uptake suggests early stage H chain ferroxidase activity and second stage L chain cooperation. Biometals. 2004;17(2):129–34.
47. Jones BM, Worwood M, Jacobs J. Serum ferritin in patients with cancer: determination with antibodies to HeLa cell and spleen ferritin. Clin Chim Acta. 1980;106(2):203–14.
48. Arosio P, Yokota M, Drysdale JW. Structural and immunological relationships of isoferritins in normal and malignant cells. Cancer Res. 1976;36(5):1735–9.
49. Hann HW, Lange B, Stahlhut MW, McGlynn KA. Prognostic importance of serum transferrin and ferritin in childhood Hodgkin’s disease. Cancer. 1990;66(2):313–6.
50. Alkhateeb AA, Leitzel K, Ali SM, Campbell-Baird C, Evans M, Fuchs EM, et al. Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy. PLoS One. 2012;7(12):e51379.
51. Alkhateeb AA, Han B, Connor JR. Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages. Breast Cancer Res Treat. 2013;137(3):733–44.
52. Kell DB, Prentorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014;6(6):748–23.
53. Nielsen P, Gunther U, Durken M, Fischer R, Dullmann J. Serum ferritin iron overload and liver damage: correlation to body iron stores and diagnostic relevance. J Lab Clin Med. 2001;138(5):413–8.
54. Chapman RW, Gorman A, Laulicht M, Hussain MA, Sherlock S, Hoffbrand AV. Binding of serum ferritin to concanavalin a in patients with iron overload and with chronic liver disease. J Clin Pathol. 1982;35(5):481–6.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions